Skip to main content

Table 1 Patient demographics and baseline charactersitics (n = 129)

From: Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial

Characteristics N (%)
Median age (range), years 63 (34 - 86)
Median time from diagnosis to PLD (range), years 5.9 (0.1 - 26.7)
Distribution of metastasis  
   Bone 84 (65)
   Liver 59 (46)
   Lymph node 54 (42)
   Lung 48 (37)
   Skin and sof tissue 42 (33)
   Pleura 30 (23)
   Abdominal* 16 (12)
   Brain 8 (6)
   Others+ 7 (5)
Metastatic sites involved  
   One 19 (15)
   Two 54 (42)
   Three 26 (20)
   Four or more sites 30 (23)
Cardiac risk factors  
   Prior anthracycline therapy 77 (60)
   Age > 60 years 74 (57)
   Hypertension 50 (39)
   Prior thoracic irradiation† 39 (30)
   History of cardiac disease 35 (27)
Median number of cardiac risk factors (range) 2 (1 - 5)
Previous therapies, setting  
   None 4 (3)
   Endocrine, adjuvant 66 (51)
   Endocrine, metastatic 84 (65)
   Endocrine (adjuvant and/or metastatic) 95 (74)
   Chemotherapy, adjuvant 77 (60)
   Chemotherapy, metastatic 99 (77)
   Chemotherapy (adjuvant and/or metastatic) 117 (91)
   Anthracycline containing (adjuvant and/or metastatic) 77 (60)
   Taxane containing (adjuvant and/or metastatic) 73 (57)
   Trastuzumab-containing (adjuvant/metastatic) 14 (11)
PLD line of chemotherapy‡  
   First 12 (9)
   Second 32 (25)
   Third 28 (22)
   Fourth and higher 57 (44)
Median number of PLD cycles (range)§ 6 (1-6)
Median cumulative PLD dose, mg/m2 (range) § 210 (25 - 300)
  1. *Including patients with peritoneal, ovarian and intestinal metastasis; +pericardial (n = 3), bone marrow (n = 3) and meningeal involvement (n = 1); including patients with adjuvant irradiation of the breast; adjuvant chemotherapy was counted as prior therapy line
  2. §PLD cycles within extension therapy (n = 17) not included.